Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group study 8821

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2144-2152

  Parsons, S K ^a   Gelber, S ^a   Cole, B F ^a   Ravindranath, Y ^a   Ogden, A ^a   Yeager, A M ^a   Chang, M ^a   Shuster, J ^a   Weinstein, H J ^a   Gelber, R D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MODEL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PATIENT EDUCATION; PATIENT SELECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0033024372     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2144     Document Type: Article

References (44)

1. Woods WG, Kobrinsky N, Buckley J. et al: Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodys-plastic syndrome: A Children's Cancer Group pilot study. J Clin Oncol 11:1448-1457, 1993
2. Rowe JM, Tallman MS: Intensifying induction therapy in acute myeloid leukemia: Has a new standard of care emerged? Blood 90:2121-2126, 1997
3. Creutzig U, Ritter J, Riehm H, et al: Improved treatment results in childhood acute myelogenous leukemia: A report of the German Cooperative Study AML-BFM-78. Blood 65:298-304, 1985
4. Vormoor J, Boos J, Stahnke K, et al: Therapy of childhood acute myelogenous leukemia. Ann Hematol 73:11-24, 1996
5. Nesbit ME Jr, Buckley JD, Feig SA, et al: Chemotherapy for induction of remission of childhood leukemia followed by bone marrow transplantation or multiagent chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 12:127-135, 1994
6. Wells RJ, Woods WG, Buckley JD, et al: Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Children's Cancer Group Study. J Clin Oncol 12:2367-2377, 1994
7. Feig SA, Lampkin B, Nesbit ME, et al: Outcome of BMT during first complete remission of AML: A comparison of two sequential studies by the Children's Cancer Group. Bone Marrow Transplant 12:65-71, 1993
8. Dinndorf P, Bunin N: Bone marrow transplantation for children with acute myelogenous leukemia. J Pediatr Hematol Oncol 17:211-224, 1995
9. McGlave PB, Haake RJ, Bostrom BC, et al: Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 72:1512-1517, 1988
10. Dini G, Abla O, Uderzo C, et al: Allogeneic bone marrow transplantation in children with AML: Italian experience. Bone Marrow Transplant 7:76-77, 1991 (suppl 3)
11. Dahl GV, Kalwinsky DK, Mirro J Jr , et al: Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission J Clin Oncol 8:295-303, 1990
12. Michael G, Gluckman E, Blaise D, et al: Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: A report from the Groupe D'etude Des Greffes De Moelle Osseuse. J Clin Oncol 10:1865-1869, 1992
13. Santos GW, Tutschka PJ, Brookmeyer R, et al: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347-1353, 1983
14. Amadori S, Testi AM, Arico M, et al: Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 11:1046-1054, 1993
15. Lowenberg B, Verdonck LJ, Dekker AW, et al: Autologous bone marrow transplantation in acute myeloid leukemia in first remission: Results of a Dutch prospective study. J Clin Oncol 8:287-294, 1990
16. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217-223, 1995
17. Appelbaum RA, Fisher LD, Thomas D: Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: A five-year follow-up - Seattle Marrow Transplant Team. Blood 72:179-184, 1988
18. Mayer RJ: Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: Is there a "best choice?" J Clin Oncol 6:1532-1536, 1988
19. Begg CB, McGlave PB, Bennett JM, et al: A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia. J Clin Oncol 2:369-378, 1984
20. Petersen FB, Lynch MHE, Clift RA, et al: Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. J Clin Oncol 11:1353-1360, 1993
21. Reiffers J, Gaspard MH, Maraninchi D, et al: Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: A prospective control trial. Br J Haematol 72:57-63, 1989
22. Harousseau J-L, Cahn J-Y, Pignon B, et al: Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy for adult acute myeloid leukemia. Blood 90:2978-2986, 1997
23. Vowels M, Stevens M, Tiedemann K, et al: Autologous and allogeneic bone marrow transplantation for childhood acute nonlymphoblastic leukemia. Transplant Proc 24:184-185, 1992
24. Hermans J, Suciu S, Stijnen TH, et al: Treatment of acute myelogenous leukemia: An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Clin Oncol 25:545-550, 1989
25. Ravindranath Y, Yeager AM, Chang MN, et al: Autologous bone marrow transplantation versus intensive chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 334:1428-1434, 1996
26. Goldhirsch A, Gelber RD, Simes RJ, et al: Costs and benefits of adjuvant therapy for breast cancer: A quality-adjusted survival analysis. J Clin Oncol 7:36-44, 1989
27. Gelber RD, Goldhirsch A, Cole BF, et al: A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 88:1039-1045, 1996
28. Lenderking WR, Gelber RD, Cotton DJ, et al: Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 330:738-743, 1994
29. Cole BF, Gelber RD, Kirkwood JM, et al: Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 14:2666-2673, 1996
30. Ogden AK, Parsons SK, Ravindranath Y, et al: Busulfan and cyclophosphamide conditioning for allogeneic transplantation in children with acute myelogenous leukemia in first complete remission. J Cell Biochem Suppl 18B:64, 1986 (abstr)
31. Ferrant A, Doyen C, Delannoy A, et al: Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission. Bone Marrow Transplant 7:303-309, 1991
32. Sierra J, Brunet S, Granena A, et al: Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. J Clin Oncol 14:1353-1363, 1996
33. Shulman HM, Sullivan KM, Weiden PL, et al: Chronic graft versus host syndrome in man: A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 69:204-217, 1980
34. Shuster JJ: Median follow-up in clinical trials. J Clin Oncol 9:191-192, 1989
35. Gelber RD, Cole BF, Gelber S, et al: Comparing treatments using quality-adjusted survival: The Q-TWiST method. Am Statist 49:161-169, 1995
36. Kaplan SH, Barlow SE, Parsons S, et al: Assessing functional status and health-related quality of life among school-aged children: Reliability and validity of a new self-reported measure. International Society for Quality of Life Research, Montreal, Canada, October 1995 (abstr presentation)
37. Fenaux P, Preudhomme C, Lai JL, et al: Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: A Report on 283 Cases. Br J Haematol 73:61-67, 1989
38. Arthur DC, Berger R, Golomb HM, et al: The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 40:203-216, 1989
39. Stasi R, Del Poeta G, Masi M, et al: Incidence abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet Cytogenet 67:28-34, 1993
40. Marosi C, Koller U, Koller-Weber E, et al: Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 61:14-25, 1992
41. Marlton P, Keating M, Kantarjian H, et al: Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 9:965-971, 1995
42. Swansburry GJ, Lawler SD, Alimena G, et al: Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 73:1-7, 1994
43. Ferrant A, Labopin M, Frassoni F, et al: Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission - A European Group for Blood and Marrow Transplantation study. Blood 90:2931-2938, 1997
44. Gale RP, Horowitz MM, Weiner RS, et al: Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 16:203-208 1995